-
After drinking tea for thousands of years, is it anti-cancer or carcinogenic?
Time of Update: 2021-03-20
Recently, a new study by the University of California, Irvine, showed that the compounds in green tea and black tea can relax blood vessels by activating ion channel proteins in the blood vessel walls.
In February 2021, a study published in Nature Communications showed that EGCG in green tea may enhance the anti-cancer activity of p53.
-
Br J Cancer: ADI-PEG20 combined with cisplatin in the treatment of metastatic malignant solid tumors
Time of Update: 2021-03-20
Pharmacodynamic results of the combination treatment cohortAll in all, the results of the study revealed that ADI-PEG20 and cisplatin taken at the same time have acceptable safety and have shown anti-tumor activity against metastatic ASS1-deficient solid tumors.
-
Int J Cancer: The impact of neoadjuvant system therapy on the prognosis of gastrointestinal stromal tumors
Time of Update: 2021-03-20
. Although the risk of NAT patients is higher, this analysis shows that neoadjuvant system therapy for localized GIST patients is associated with a moderate survival benefit and a lower 90-day postoperative mortality rate, and does not affect the possibility of R0 resection.
-
JAHA: Cardiotoxic effects of anthracyclines on left ventricular ejection fraction
Time of Update: 2021-03-20
do?w=%E5%BF%83%E8%A1%80%E7%AE%A1">heart blood vessels published a research article on the disease areas authoritative magazine JAHA, researchers systematically searched three databases (CENTRAL, MEDLINE and SCOPUS) to determine and evaluate the cardioprotective agent for cardiac toxicity compared to placebo preventive action Randomized trials.
-
Li Weimin, deputy to the National People's Congress: It is recommended to include lung cancer screening in medical insurance reimbursement
Time of Update: 2021-03-20
At the same time, Representative Li Weimin told reporters that in 2019, West China Hospital will have to do three major things: The first thing is to deepen the construction of Internet hospitals and provide patients with more convenient services through the Internet.
-
Opdivo (nivolumab) combined with Cabometyx (cabozantinib) in the first-line treatment of advanced renal cell carcinoma, CHMP holds positive opinions
Time of Update: 2021-03-20
The results showed that, compared with sunitinib , the progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) of patients in the Opdivo (nivolumab) combined with Cabometyx (cabozantinib) group were significantly improved.
-
Gastric Cancer: Phase 3 | The efficacy of fluorouracil/thiopiperidine in the treatment of metastatic gastroesophageal junction cancer
Time of Update: 2021-03-20
The TAGS trial recruited mGC or mGEJC patients who had previously been treated with 2-line or above chemotherapy, and were randomized (2:1) to receive FTD/TPI or placebo treatment, while giving the best supportive treatment.
-
1.2 million people die of liver cancer each year in the world. Two cups of coffee a day will reduce the number of deaths due to liver cancer by hundreds of thousands
Time of Update: 2021-03-20
Researchers found through statistical data that drinking two or three cups of coffee a day can reduce a person's risk of liver cancer by 38%, and the risk of liver cancer death by 46%.
-
Eur Radiol: Can gadolinium disodium-enhanced MRI-enhanced postoperative prognostic evaluation of liver cancer be applied to multicenters?
Time of Update: 2021-03-20
Recently, a study published in the journal European Radiology clarified the clinical and histopathological prognostic factors of patients with multicenter multiple hepatocellular carcinoma (HCC) after surgical resection, and evaluated specific imaging-related factors (including arterial Apparent enhancement (APHE) and gadoxetate disodium enhance the LI-RADS category of each lesion on MRI) can provide additional prognostic information when diagnosing multicenter HCC.
-
Lancet Gastroenterol Hepatol: Is it necessary for patients with advanced esophageal cancer to undergo palliative radiotherapy after esophageal stent placement?
Time of Update: 2021-03-19
preventionThis is a multicenter, open-label phase 3 randomized controlled trial that recruited incurable esophageal cancer patients 16 years of age and older who received SMS implantation as the primary management measure for dysphagia , and 1:1 randomized stent implantation Later, he received only routine care or additional EBRT (20 Gy, 5 times; or 30 Gy, 10 times).
-
Eur Radiol: standardized percutaneous microwave ablation for lung tumors
Time of Update: 2021-03-19
Percutaneous Thermal Ablation Percutaneous Thermal Ablation Recently, a study published in the journal European Radiology prospectively evaluated the reproducibility, safety and effectiveness of MWA in the treatment of unresectable primary and secondary lung tumors, providing a new way to establish a standardized MWA treatment plan.
-
Br J Cancer: Analysis of the safety and efficacy of temozolomide and nabiximols cannabinoid spray in the treatment of recurrent glioblastoma
Time of Update: 2021-03-19
This study aims to evaluate the safety and preliminary efficacy of nabiximols cannabinoid spray and a booster dose of temozolomide (DIT) in GBM patients who have relapsed for the first time.
-
Bayer had a net loss of approximately 10.5 billion euros last year, and the top sales of rivaroxaban faced a patent cliff
Time of Update: 2021-03-19
However, the top-selling rivaroxaban patent has expired in China in 2020, and it will also expire in EU countries in 2023, the United States in 2024, and Japan in 2025.
Bayer pointed out in its financial report that the patents of aflibercept and sorafenib, including rivaroxaban, have expired in China in 2020.
-
Eur Radiol: tumor surface mucosal enhancement sign-a high-risk predictor of gastrointestinal stromal tumors
Time of Update: 2021-03-19
Table 2 Multivariate logistic regression analysis predicts the high-risk stratification of gastric stromal tumors.
Incomplete OEGM signs are an independent predictor of the high-risk stratification of gastric GISTs, and are closely related to pathological mucosal changes.
-
Nat Commun: Immune cell analysis of cerebrospinal fluid can characterize the microenvironment of brain metastases
Time of Update: 2021-03-19
Tumor immunityIdentification of tumor immune infiltration patterns in brain metastasesAll in all, the results of the study revealed that CSF immune cell analysis can provide a non-invasive alternative to predict patient response to ICI and determine the presence of clonal T cell receptors in brain metastases.
-
Science: It can target RAS and p53 protein receptors, and the bispecific antibody research has made another breakthrough!
Time of Update: 2021-03-19
In order to target mutant RAS and p53 protein fragments, the researchers designed bispecific antibodies.
-
Eur Radiol: There is a short-term recurrence after radical resection of liver cancer. How do you evaluate it before surgery?
Time of Update: 2021-03-19
Pancreatic cancerGastric cancer blood vessel Recently, a study published in the journal European Radiology showed that the standardized iodine concentration (NIC) extracted from the angiogenesis analysis of HCC lesions is related to the tumor microvessel density and early recurrence of HCC patients, thus confirming that NIC can be used as an early recurrence after surgical resection.
-
Eur Radiol: How to reliably predict the survival rate of advanced hepatocellular carcinoma treated with sorafenib
Time of Update: 2021-03-19
Recently, a study published in the journal European Radiology compared the 1D and 3D quantitative tumor response criteria of DCE-MRI in patients with advanced liver cancer treated with sorafenib to predict the overall survival (OS) in the early stage of treatment.
-
Eur Radiol: Can only PET be used for screening of bone metastases in middle and high-risk prostate cancer?
Time of Update: 2021-03-19
Recently, a study published in the journal European Radiology evaluated the incidence and distribution of bone metastases in untreated prostate cancer patients using whole-body MRI for metastatic examination, and evaluated the results according to current guidelines.
-
SMO inhibitor’s application for marketing was given priority review by CDE for treatment of basal cell carcinoma
Time of Update: 2021-03-19
Today, Shanghai Jiyu Medicine/Sun Pharma’s application for the listing of Sonny Deji Phosphate Capsules (trade name: Odomzo) was included in the priority review by CDE and started to be publicized for use in adult patients with locally advanced basal cell carcinoma (BCC) recurring after surgery or radiotherapy.
